Cargando…
Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States
Biologic therapies have been available for inflammatory bowel disease for >20 years, but patient outcomes have not changed appreciably over this time period. To better understand medication utilization for this disease, we evaluated a novel technique for visualizing treatment pathways, including...
Autores principales: | Siegel, Corey A., Yang, Fei, Eslava, Sergio, Cai, Zhaohui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145024/ https://www.ncbi.nlm.nih.gov/pubmed/32463619 http://dx.doi.org/10.14309/ctg.0000000000000128 |
Ejemplares similares
-
Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States
por: Patel, Haridarshan, et al.
Publicado: (2017) -
Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting
por: Rubin, David T., et al.
Publicado: (2020) -
Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016) -
Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010–2014
por: Akhuemonkhan, Eboselume, et al.
Publicado: (2017) -
Increasing thirty-day readmissions of Crohn’s disease and ulcerative colitis in the United States: A national dilemma
por: Dahiya, Dushyant Singh, et al.
Publicado: (2022)